MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference

YAVNE, Israel, August 20, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat, hosted by Swayampakula Ramakanth, Managing Director, Senior Equity Research Analyst, on Monday, September 8, 2025 at 4:30p.m. ET at the H.C. Wainwright 27^th Annual Global Investment Conference.

A live webcast of the event will be accessible both and on MediWound’s website, under the page of the Investors section. 

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair. The company’s FDA-approved biologic, NexoBrid^®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the U.S., European Union, Japan, and other international markets. MediWound is also advancing EscharEx^®, a late-stage investigational therapy for the debridement of chronic wounds. EscharEx has demonstrated clinical advantages over the leading enzymatic debridement product and targets a substantial global market opportunity.

For more information visit  and follow us on .

MediWound Contacts:                                                                       

Hani Luxenburg                                                                        Daniel Ferry

Chief Financial Officer                                                             Managing Director

MediWound Ltd.                                                                        LifeSci Advisors, LLC

                                                                 

Media Contact:

Ellie Hanson

FINN Partners for MediWound